Long-term survival outcomes of duodenal adenocarcinoma: A cohort study with 15-year single-center experience

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

195

Figures (1-3)

Tables (1-2)

Sum=375

Publishing Process of This Article

Item

Count

Browse

Download

Sum=47

Feb 27, 2025 (publication date) through Feb 24, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Surg. Feb 27, 2025; 17(2): 101365
Published online Feb 27, 2025. doi: 10.4240/wjgs.v17.i2.101365

Table 1 Characteristics of the patients with duodenal adenocarcinoma

Variable	n (%)
Age, mean (SD)	60.7 (12.5)
Female gender, n (%)	85 (40.9)
BMI (kg/m²), mean (SD)	22.9 (3.8)
Preoperative lab, n (%)
CA199 (U/mL) > 37	50 (24.0)
CEA (ug/L) > 5	64 (30.8)
Operational types, n (%)
Pancreatoduodenectomy	123 (71.5)
Local resection	19 (11.1)
Palliative operation	30 (17.4)
Radical operation, n (%)	142 (82.6)
Total number of harvested lymph nodes, median (IQR)	12 (8-16)
Positive lymph nodes, n (%)	51 (35.9)
Tumor stage, n (%)
Stage I	54 (26.0)
Stage II	43 (20.7)
Stage III	57 (27.4)
Stage IV	54 (26.0)
Tumor location, n (%)
1^st portion	99 (47.6)
1^st-2^nd portion	64 (30.8)
2^nd portion	13 (6.3)
3^rd portion	5 (2.4)
4^th portion	27(13.0)
Postoperative complications, n (%)	46 (32.2)
Hospital stays (days), mean (SD)	22.5 (5.1)
Pathological type¹, n (%)
Adenocarcinoma	147 (85.5)
Non-adenocarcinoma	25 (14.5)
Pathological differentiation², n (%)
Poorly differentiation	41 (28.9)
Medium-high differentiation	101 (71.1)
Pancreatic invasion, n (%)	68 (47.7)
Vascular invasion, n (%)	50 (35.5)
Nerve invasion, n (%)	69 (48.3)
Lymphatic vessel invasion³, n (%)	51(35.9)
KRAS mutation, n (%)	6 (15.38)
DMMR/MSI-H, n (%)	7 (7.22)
Her-2 positive, n (%)	56 (49.12)
Ki-67 mutation, n (%)	7 (20.59)
Adjuvant therapy, n (%)	26 (18.3)

¹Missing value in overall cohort: 3.

²Missing value in overall cohort: 5.

³Missing value in overall cohort: 10.

Citation: Xie QF, Long LS, Luo YY, Lu MT, Ming WK, Zhao LY, Liu H. Long-term survival outcomes of duodenal adenocarcinoma: A cohort study with 15-year single-center experience. World J Gastrointest Surg 2025; 17(2): 101365
URL: https://www.wjgnet.com/1948-9366/full/v17/i2/101365.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i2.101365